Analysis
Roivant Reports Q3 Results, Cites Phase 2 Breakthrough and Catalyst-Rich 2026
Roivant Sciences (Nasdaq: ROIV) reported its financial results for the fiscal third quarter ended December 31, 2025, underscored by positive...